Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Adrian L Harris

Showing results (11-20 of 464) with videos related to

Pageof 47
Sort By:
Nature|November 16, 2012
How cancer metabolism is tuned for proliferation and vulnerable to disruptionAlmut Schulze, Adrian L Harris
EMBO Molecular Medicine|February 21, 2015
Metabolic and hypoxic adaptation to anti-angiogenic therapy: a target for induced essentialityAlan McIntyre, Adrian L Harris
Endocrine-Related Cancer|January 30, 2007
Role of hypoxia-inducible factor-1alpha as a cancer therapy targetShalini Patiar, Adrian L Harris
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 3, 2007
The unfolded protein response and integrated stress response to anoxiaTomasz Rzymski, Adrian L Harris
Annual Review of Pharmacology and Toxicology|January 28, 2004
Novel angiogenic signaling pathways and vascular targetsRoy Bicknell, Adrian L Harris
Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer|August 26, 2016
The Role of pH Regulation in Cancer ProgressionAlan McIntyre, Adrian L Harris
Current Opinion in Pharmacology|July 20, 2002
Drug inhibition of angiogenesisSrinivasan Madhusudan, Adrian L Harris
Oncology (Williston Park, N.Y.)|September 4, 2014
Cancer metabolism as a therapeutic target: metabolic synthetic lethalityKarim Bensaad, Adrian L Harris
Cancer Chemotherapy and Pharmacology|November 25, 2003
The cardiovascular safety of high-dose intravenous granisetron in cancer patients receiving highly emetogenic chemotherapyJames Carmichael, Adrian L Harris
Anti-Cancer Drugs|October 11, 2003
High-dose i.v. granisetron for the prevention of chemotherapy-induced emesis: cardiac safety and tolerabilityJames Carmichael, Adrian L Harris
Pageof 47

Showing results (11-20 of 464) with videos related to

Sort By:
Pageof 47
Nature|November 16, 2012
How cancer metabolism is tuned for proliferation and vulnerable to disruptionAlmut Schulze, Adrian L Harris
EMBO Molecular Medicine|February 21, 2015
Metabolic and hypoxic adaptation to anti-angiogenic therapy: a target for induced essentialityAlan McIntyre, Adrian L Harris
Endocrine-Related Cancer|January 30, 2007
Role of hypoxia-inducible factor-1alpha as a cancer therapy targetShalini Patiar, Adrian L Harris
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 3, 2007
The unfolded protein response and integrated stress response to anoxiaTomasz Rzymski, Adrian L Harris
Annual Review of Pharmacology and Toxicology|January 28, 2004
Novel angiogenic signaling pathways and vascular targetsRoy Bicknell, Adrian L Harris
Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer|August 26, 2016
The Role of pH Regulation in Cancer ProgressionAlan McIntyre, Adrian L Harris
Current Opinion in Pharmacology|July 20, 2002
Drug inhibition of angiogenesisSrinivasan Madhusudan, Adrian L Harris
Oncology (Williston Park, N.Y.)|September 4, 2014
Cancer metabolism as a therapeutic target: metabolic synthetic lethalityKarim Bensaad, Adrian L Harris
Cancer Chemotherapy and Pharmacology|November 25, 2003
The cardiovascular safety of high-dose intravenous granisetron in cancer patients receiving highly emetogenic chemotherapyJames Carmichael, Adrian L Harris
Anti-Cancer Drugs|October 11, 2003
High-dose i.v. granisetron for the prevention of chemotherapy-induced emesis: cardiac safety and tolerabilityJames Carmichael, Adrian L Harris
Pageof 47